Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05283980
PHASE2/PHASE3

Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement

Sponsor: Beth Israel Deaconess Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether administration of a pectoral nerve blocks (Pecs I and II) with 0.25% bupivacaine are more effective as compared to placebo to provide analgesia for cardiac implantable electronic device (CIED) placement in cardiac electrophysiology lab

Official title: Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement: A Pilot Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

62

Start Date

2022-11-17

Completion Date

2025-03

Last Updated

2024-10-01

Healthy Volunteers

Yes

Interventions

DRUG

0.25% Bupivacaine

The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline

Locations (1)

BIDMC

Boston, Massachusetts, United States